Atezolizumab

0:56
Targeting the tumor vasculature in mesothelioma
Dean Fennell
0:55
The potential of targeted and immune therapies in SCLC
Martin Reck
4:11
Limiting duration of treatment with checkpoint inhibitors: the data
Jeffrey Weber
4:25
Kidney cancer updates: avelumab/axitinib, pembro/axitinib, bevacizumab/atezo & ipilimumab/nivo
Thomas Powles
4:00
Upcoming therapies in the metastatic urothelial carcinoma space
Thomas Powles
2:25
Current therapies for advanced HCC and their limitations
Michael Pishvaian
1:48
Upcoming IO combinations for advanced HCC
Michael Pishvaian
2:40
Key outcomes of the Phase 1b of atezolizumab and bevacizumab for advanced HCC
Michael Pishvaian
1:02
Current status of VEGF inhibitor/immunotherapy combinations in RCC
Bradley McGregor
5:12
Renal cell carcinoma trial analysis: current landscape of immunotherapy combinations
Toni Choueiri
2:04
Synergy of anti-androgenic agents and immune checkpoint inhibitors in HCC
Michel Ducreux
2:41
Increased survival in metastatic NSCLC patients on immunochemotherapy seen in trials
Marina Garassino
2:24
Advancing lung cancer therapy: from palliative chemotherapy to immunotherapy
James Spicer
1:54
PD-L1 and other biomarkers for renal cell carcinoma
Hans Hammers
2:18
BRAF-positive melanoma: what’s new?
Paolo Ascierto
3:11
IMpower150: atezolizumab, chemotherapy and bevacizumab for NSCLC
Martin Reck
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals